Cargando…

Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling

New strategies for the treatment of advanced melanoma are urgently required. The RAS/RAF/MAPK pathway and c-Src are deregulated in the majority of malignant melanomas, suggesting that they may interact functionally and are involved in the development and progression of the malignancy. Preclinical st...

Descripción completa

Detalles Bibliográficos
Autores principales:	WU, JIANGHONG, LIAO, XIN, YU, BO, SU, BING
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573147/ https://www.ncbi.nlm.nih.gov/pubmed/23420605 http://dx.doi.org/10.3892/ol.2012.1066

Ejemplares similares

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
por: Algazi, A P, et al.
Publicado: (2012)

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

HOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib
por: deBlacam, C, et al.
Publicado: (2011)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
por: Dosch, Austin R., et al.
Publicado: (2019)

Dasatinib regulates the proliferation and osteogenic differentiation of PDLSCs through Erk and EID3 signals
por: Jia, Linglu, et al.
Publicado: (2023)

MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia
por: Fang, Yanfen, et al.
Publicado: (2013)

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)
por: Qian, Xiao-Long, et al.
Publicado: (2017)

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021)

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
por: XIAO, JUAN, et al.
Publicado: (2015)

Predictive biomarkers for dasatinib treatment in melanoma
por: Eustace, Alex J., et al.
Publicado: (2014)

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice
por: Lee, Dajeong, et al.
Publicado: (2020)

Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation
por: Fu, Yang, et al.
Publicado: (2018)

Correction: Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src
por: Perez, Marco, et al.
Publicado: (2016)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity
por: Calizo, Rhodora C., et al.
Publicado: (2019)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway
por: Sun, Yifeng, et al.
Publicado: (2014)

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
por: Kadife, Elif, et al.
Publicado: (2019)

Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury
por: Macfarlane, James G., et al.
Publicado: (2020)

The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
por: Id Boufker, Hichame, et al.
Publicado: (2010)

Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells
por: Takiguchi, Eri, et al.
Publicado: (2017)

Lipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activation
por: Lin, Tsung-Yao, et al.
Publicado: (2015)

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model
por: Scott, Aaron J., et al.
Publicado: (2017)

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma
por: Sun, Jingya, et al.
Publicado: (2018)

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion
por: Ferguson, Jennifer, et al.
Publicado: (2012)

Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging
por: McKnight, Brooke N., et al.
Publicado: (2018)

SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
por: Karwaciak, Iwona, et al.
Publicado: (2019)

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas
por: Rebecca, Vito W., et al.
Publicado: (2023)

Plasminogen activator, urokinase enhances the migration, invasion, and proliferation of colorectal cancer cells by activating the Src/ERK pathway
por: Ding, Yuanyi, et al.
Publicado: (2022)

Src Inhibitors, PP2 and Dasatinib, Increase Retinoic Acid-Induced Association of Lyn and c-Raf (S259) and Enhance MAPK Dependent Differentiation of Myeloid Leukemia Cells
por: Congleton, Johanna, et al.
Publicado: (2011)

c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus
por: Nihal, Minakshi, et al.
Publicado: (2016)

Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells
por: Chen, Bin, et al.
Publicado: (2015)

Monitoring the dynamics of Src activity in response to anti-invasive dasatinib treatment at a subcellular level using dual intravital imaging
por: Nobis, Max, et al.
Publicado: (2014)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Knockout of SRC-1 and SRC-3 in Mice Decreases Cardiomyocyte Proliferation and Causes a Noncompaction Cardiomyopathy Phenotype
por: Chen, Xian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_95t4m5iu6md2lli8bsnuagidpm